Skip to main content
CORDIS - Forschungsergebnisse der EU
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Soraprazan - a new regenerative therapy for Stargardt's disease

Ziel

Soraprazan – a new regenerative therapy for Stargardt’s disease
Abnormal accumulation of lipofuscin in the RPE cells is a hallmark in Stargardt's disease. As lipofuscin cannot be removed from the RPE cells in the eyes neither spontaneously nor with existing therapies, the accumulation of lipofuscin in the RPE cells of the eyes results in the degradation of the RPE cells and consequently in worsening of visual acuity and could lead to blindness. Soraprazan was able to show removal of lipofuscin in RPE cells. Aim of the phase II trial in this project is to evaluate savety and efficacy or orally taken Soraprazan treatment compared to placebo.

Aufforderung zur Vorschlagseinreichung

H2020-SC1-2016-2017

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SC1-2017-Single-Stage-RTD

Koordinator

EBERHARD KARLS UNIVERSITAET TUEBINGEN
Netto-EU-Beitrag
€ 467 500,00
Adresse
GESCHWISTER-SCHOLL-PLATZ
72074 Tuebingen
Deutschland

Auf der Karte ansehen

Region
Baden-Württemberg Tübingen Tübingen, Landkreis
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
€ 467 500,00

Beteiligte (11)